Barclays PLC Buys 188,421 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Barclays PLC increased its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 31.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 790,957 shares of the company's stock after purchasing an additional 188,421 shares during the quarter. Barclays PLC owned approximately 0.65% of 10x Genomics worth $11,357,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in TXG. Signaturefd LLC lifted its stake in shares of 10x Genomics by 424.6% during the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock worth $26,000 after buying an additional 1,452 shares during the last quarter. Blue Trust Inc. lifted its stake in 10x Genomics by 73.1% during the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after purchasing an additional 1,299 shares during the last quarter. Sound Income Strategies LLC grew its position in 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock valued at $48,000 after acquiring an additional 1,330 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in 10x Genomics during the 4th quarter worth approximately $52,000. Finally, SRS Capital Advisors Inc. increased its holdings in shares of 10x Genomics by 817.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock worth $70,000 after buying an additional 4,324 shares in the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Trading Down 0.1 %

TXG stock traded down $0.01 during mid-day trading on Friday, reaching $8.30. The company's stock had a trading volume of 3,016,064 shares, compared to its average volume of 2,258,752. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -5.46 and a beta of 2.01. 10x Genomics, Inc. has a 12 month low of $6.78 and a 12 month high of $29.37. The business's 50 day moving average price is $9.47 and its 200 day moving average price is $13.11.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, equities analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on TXG shares. Leerink Partners lowered 10x Genomics from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $25.00 to $12.00 in a research report on Thursday, February 13th. Stifel Nicolaus reduced their price target on 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Barclays dropped their price objective on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. UBS Group decreased their price target on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating for the company in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. dropped their price target on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, 10x Genomics presently has a consensus rating of "Hold" and a consensus target price of $19.79.

Insider Activity

In other 10x Genomics news, Director Alan Mateo purchased 40,000 shares of the firm's stock in a transaction on Friday, February 21st. The stock was acquired at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the purchase, the director now owns 61,691 shares of the company's stock, valued at $687,237.74. This trade represents a 184.41 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the transaction, the insider now directly owns 335,324 shares in the company, valued at $3,712,036.68. This trade represents a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.03% of the stock is currently owned by company insiders.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.